Skip to Navigation
London School of Hygiene & Tropical Medicine Malaria Centre

Malaria clinical trials and studies

Pharmacokinetics of sulfadoxinepyrimethamine plus amodiaquine when used for Seasonal Malaria Chemoprevention (SMC) in children.

LSHTM investigators:
Issaka Zongo, Harparkash Kaur, Neal Alexander, Badara Cisse & Paul Milligan.
External collaborators:
Jean Louis NDiaye & Oumar Gaye (Université Cheikh Anta Diop, Senegal).

Sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) is the most effective regimen for Seasonal Malaria Chemoprevention (SMC), but there is little information about the pharmacokinetics of these drugs in children.

This information is important in order to check the bioavailability of the two drugs when used for SMC and to check the adequacy of the currently recommended dosage and to determine the duration of therapeutic levels. To determine the pharmacokinetic profile of sulfadoxine, pyrimethamine, and desethyl amodiaquine, 150 children 3-59 months of age were given one course of treatment with SP+AQs and were followed-up for one month. Finger prick blood samples were taken on four occasions for measurement of drug concentrations by HPLC using photo-diode array detection and samples of the drugs drugs were tested to make sure of their bioavailability.